- 抗体药物复合体 -
As more Antibody-Drug Conjugates head to market, the next-generation of ADCs looms on the horizon. Next-gen engineering requires designing an optimal antibody, payload, linker and conjugation method while ensuring stability, targeted delivery, and limited off-target effects. The “Next-Generation Antibody-Drug Conjugates” conference explores the engineering finesse required to achieve improved therapeutics while adhering to the underlying biology that research has uncovered, showing the way to more potent and efficacious molecules. Case Studies and data will be shared that exemplify the ongoing efforts to engineer ADCs, move them into the clinic, and fight cancer along with potentially non-oncological indications.
Plenary Keynote Session
Moderator's Opening Remarks
Janine Schuurman, PhD, Corporate Vice President, Research & Innovation, Genmab BV
Bicycles and Bicycle Drug Conjugates
Sir Gregory Winter, PhD, FRS, Master, Trinity College; Co-Founder and Director, Bicycle Therapeutics
Using Protein Engineering to Make Therapeutics in Situ
Andreas G. Plückthun, PhD, Professor and Director, Department of Biochemistry, University of Zürich
THE NEXT GENERATION OF ADCs
Strategies & Challenges for the Next Generation of ADCs
Alain Beck, PhD, Head, Physico-Chemistry, Pierre Fabre
Functional Disulfide Re-Bridging Enables Native Full Antibody DAR 2, 4 & 8 Formation, Site-Selective Orthogonal Dual Modification and Homogeneous Fragment Drug Conjugates, as well as Bi- and Tri-Specific Scaffolds
Vijay Chudasama, PhD, Lecturer, Chemistry, University College London
FIGHTING CANCER WITH ADCs
Delineating the Role of Normal Tissue Target Expression on PK and Anti-Tumor Activity with a Mouse Cross-Reactive ADC
Jan Pinkas, PhD, Vice President, Translational Research & Development, ImmunoGen, Inc.
Clinical and Preclinical Evaluation of Anti-Tumor Antibody-Toxin Fusion Proteins
Gregory P. Adams, PhD, CSO, Eleven Biotherapeutics, Inc.
Radionuclide Therapy Using Peptide Nucleic Acid (PNA)-Mediated Pre-Targeting of HER2-Expressing Tumors
Amelie Eriksson Karlström, PhD, Professor, Protein Science, Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology
POTENT PAYLOAD DESIGN
New Payloads for Antibody-Drug Conjugates
Thomas Pillow, PhD, Senior Scientist, Discovery Chemistry, Genentech, Inc.
Preclinical Validation of Site- Specifically Conjugated ADCs with Potent Anthracycline Payloads in Solid and Hematologic Tumor Models
Roger Beerli, PhD, Chief Scientific Officer, NBE-Therapeutics AG
BREAKTHROUGH ADC ENGINEERING
Utility of PK-PD Modeling and Simulation (M&S) in the Discovery and Development of Next-Generation Immunoconjugates (ICs) for Cancer Therapy
Aman P. Singh, PhD, PK-PD Scientist/Biologics Development Leader, Janssen Biotherapeutics
Site-Specific Antibody Functionalization at the Antibody NBS
Nathan J. Alves, PhD, Assistant Professor, Emergency Medicine and Biomedical Engineering, Indiana University School of Medicine
Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins
Harald Kolmar, PhD, Professor and Head, Applied Biochemistry, Technical University of Darmstadt